Category Archives: Stem Cell Videos

SAN FRANCISCO, CA ( Ivanhoe Newswire) -- Stem cells, they could hold the key to the treatment and cure of more than 70 major diseases and conditions. A science  lab is taking stem cell technology another step into the future.

From broken hearts.

"One artery was completely blocked," Elmer Goodman, a heart disease patient, told Ivanhoe.

To severed spines.

"It was just like somebody took a tarp from the bottom of my neck and just peeled it back and took all the feeling from me," John Miksa, who is paralyzed, said.

To damaged brains.

"I was going to be drooling on a bib, in a wheelchair for the rest of my life," Erwin Velbis, a stroke survivor, said.

The answer to heal them all may be found inside a lab.

"We had a major breakthrough," Deepak Srivastava, M.D., from the Gladstone Institute of Cardiovascular Disease, said.

Doctor Deepak Srivastava and doctor Sheng Ding are two of the many  minds at Gladstone Institute using not adult stem cells or embryonic stem cells, but your own skin cells to repair bodies from the inside out.

"It means in the future one might be able to create new heart cells, new lung cells, new spinal cord cells, starting with your own cells from your skin," Dr. Srivastava said.

Doctor Srivastava is taking adult skin cells, and turning them into beating heart cells.  It's called direct reprogramming.

"We've been able to create a beating heart cells that used to be on someone's skinwhich is really like science fiction," Dr. Srivastava said.

The same approach could be used to repair spinal cord injuries and practically any other part of the body.

"We've been working on new methods that can convert cells from the skin to brain cells," Sheng Ding, Ph.D., at the Gladstone institute, said.

Doctor Ding has transformed the adult skin cells into neurons that are capable of transmitting brain signals. They hope this could reverse the effects of Alzheimer's, Parkinson's and stroke.

"It's the ultimate in personalized medicine," Dr. Srivastava said.

Doctors say because they're using a patient's own skin cells, there's little to no chance of rejection. These skin cells could also be used to test new drugs and each patient's possible response to those drugs.  Allowing doctors to better personalize medicine. MORE

More Information

Click here for additional research on Skin Cells as Stem Cells! Medicine's Next Big Thing

Click here for Ivanhoe's full-length interview with Dr. Deepak Srivastava

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Marsha Hitchcock at mhitchcock@ivanhoe.com

Follow this link:
Skin Cells as Stem Cells! Medicine's Next Big Thing

30-01-2012 08:31 US: Senomyx's Fake Flavors http://www.corpwatch.org China: Businesses Sell Aborted Babies as Stamina Booster Pills http://www.lifenews.com Pepsi Uses Aborted Fetal Cells In Flavor Enhancers govtslaves.info Products and Companies that use Aborted Fetuses brie-hoffman.hubpages.com Senomyx Website http://www.senomyx.com

See the article here:
Baby Stem Cell Franken-food - Pepsi, Coke, Nestle, Starbucks

NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM
-
News) today announced the publication of preclinical data
demonstrating that its proprietary HuCNS-SC(R) cells (purified
human neural stem
cells) protect host photoreceptors and preserve vision
in an animal model of retinal disease. The preclinical
results are highly relevant to human disorders of vision loss,
the most notable of which is dry age-related macular degeneration
(AMD). The study is available online at
http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract
and will be featured as the cover article in the February issue
of the international peer-reviewed European Journal of
Neuroscience.

This research was conducted in collaboration with a team of
researchers led by Raymond Lund, Ph.D., Professor Emeritus of
Ophthalmology, and Trevor McGill, Ph.D., Research Assistant
Professor at the Casey Eye Institute, Oregon Health and Science
University.

The results of the study show that photoreceptors, the key
cells of the eye involved in vision, were protected from
degeneration following transplantation of HuCNS-SC cells into
the Royal College of Surgeons (RCS) rat. The RCS rat is a
well-established model of retinal disease which has been used
extensively to evaluate potential cell therapies. Moreover, the
number of cone photoreceptors, which are responsible for
central vision, remained constant over an extended period,
consistent with the sustained visual acuity and light
sensitivity observed in the study. In humans, degeneration of
the cone photoreceptors account for the unique pattern of
visual loss in dry AMD.

"These results are the most robust shown to date in this animal
model," said Dr. Lund, one of the study's lead investigators.
"One of the more striking findings is that the effect on vision
was long-lasting and correlated with the survival of HuCNS-SC
cells more than seven months after transplantation, which is
substantially longer than other cell types transplanted into
this same model. Also important, particularly for potential
clinical application, was that the cells spread from the site
of initial application to cover more of the retina over time.
These data suggest that HuCNS-SC cells appear to be a
well-suited candidate for cell therapy in retinal degenerative
conditions."

Alexandra Capela, Ph.D., another of the study's investigators
and a senior scientist at StemCells, commented, "This study
showed that the HuCNS-SC cells persisted and migrated
throughout the retina, with no evidence of abnormal cell
formation, which supports our hypothesis of a single transplant
therapeutic. With this research, then, we have shown that
vision can be positively impacted with a simple approach that
does not require replacing photoreceptors or the RPE cells. We
look forward to investigating this promising approach in the
clinic later this year."

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and
commercialization of cell-based therapeutics and tools for use
in stem cell-based research and drug discovery. The Company's lead
therapeutic product candidate, HuCNS-SC(R) cells (purified
human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system
disorders. Clinical trials are currently underway in spinal
cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children. In addition, the Company
plans to initiate a clinical trial of HuCNS-SC cells in the dry
form of age-related macular degeneration in 2012, and is also
pursuing preclinical studies of its HuCNS-SC cells in
Alzheimer's disease. StemCells also markets stem cell research
products, including media and reagents, under the SC Proven(R)
brand, and is developing stem cell-based assay platforms for
use in pharmaceutical research, drug discovery and drug
development. Further information about StemCells is available
at
http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this
press release constitutes forward-looking statements within the
meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to
the safe harbors created therein. These statements include, but
are not limited to, statements regarding the prospect of the
Company's HuCNS-SC cells to preserve vision in animal models of
retinal disease; the prospect of successful results from this
research collaboration and advancing to clinical testing in
age-related macular degeneration or other retinal disease; the
potential of the Company's HuCNS-SC cells to treat a broad
range of central nervous system disorders; the prospect and
timing associated with initiating a clinical trial in a retinal
disorder; and the future business operations of the Company,
including its ability to conduct clinical trials as well as its
other research and product development efforts. These
forward-looking statements speak only as of the date of this
news release. The Company does not undertake to update any of
these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks
and uncertainties to which the Company is subject, including
the fact that additional trials will be required to demonstrate
the safety and efficacy of the Company's HuCNS-SC cells for the
treatment of any disease or disorder; uncertainty as to whether
the results of the Company's preclinical studies in retinal
disease will be replicated in humans; uncertainty as to whether
the FDA or other applicable regulatory agencies will permit the
Company to continue clinical testing in spinal cord injury, PMD
or in future clinical trials of proposed therapies for other
diseases or conditions given the novel and unproven nature of
the Company's technologies; uncertainties regarding the
Company's ability to recruit the patients required to conduct
its clinical trials or to obtain meaningful results;
uncertainties regarding the Company's ability to obtain the
increased capital resources needed to continue its current and
planned research and development operations; uncertainty as to
whether HuCNS-SC and any products that may be generated in the
future in the Company's cell-based programs will prove safe and
clinically effective and not cause tumors or other adverse side
effects; uncertainties regarding the Company's ability to
commercialize a therapeutic product and its ability to
successfully compete with other products on the market; and
other factors that are described under the heading "Risk
Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 2010, and in its subsequent reports on
Forms 10-Q and 8-K.

Read more:
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

Read the rest here:
Vet-Stem Announces Milestone of 8,000 Animals Treated With Vet-Stem Cell Therapy

24-01-2012 09:59 CBS Early Morning Show discusses the use of adult adipose (from fat) stem cells to regrow breast tissue for use for both cosmetic reasons and reconstructive reasons as in the case of a mastectomy.

Read more:
Stem Cells Used To Regrow Breasts - Video

19-01-2012 09:27 Dr. Irv Weissman of CIRM (California Institute of Regenerative Medicine) explain the difference between adult and embryonic stem cells, how they are used and their potential.

Read the original:
Difference Between Adult and Ebryonic Stem Cells - Video

23-01-2012 20:39 Dr.

The rest is here:
Report: Adult stem cells may hold key to fountain of youth - Video

18-01-2012 15:54

Read more from the original source:
Dr. David Stevens Discusses Using Stem Cells in Regenerative Medicine - Video

17-01-2012 13:20 Researchers from the University of Pittsburgh School of Medicine found that a shot of young stem cells made rapidly aging mice live longer and healthier. Johnny Huard, Ph.D., professor in the Departments of Orthopaedic Surgery and of Microbiology and Molecular Genetics, Pitt School of Medicine, and director of the Stem Cell Research Center at Pitt and Children's Hospital of Pittsburgh of UPMC, and Laura Niedernhofer, MD, Ph.D., associate professor in the University of Pittsburgh's Department of Microbiology and Molecular Genetics and the University of Pittsburgh Cancer Institute (UPCI), discuss their research findings, which were published in the Jan

Read the original here:
Young stem cells make rapidly aging mice live longer and healthier - Video

09-01-2012 06:59 DigInfo TV - diginfo.tv 16

See original here:
Efficiently Culturing Neural Stem Cells on Fine Rubber Surface Structure #DigInfo - Video